Hormone receptor-positive/HER2-negative (HR+/HER2−) tumors represent 65–70% of all breast cancers [3], with 9–10% of patients harboring germline breast cancer susceptibility gene (BRCA) mutations [4, 5]. This evidence concerns the gene ERBB2 and breast cancer.